| 臺大學術典藏 |
2022-09-15T01:09:02Z |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
|
Petrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.A.; Fl?chon A.; Bamias A.; Yu E.Y.; van der Heijden M.S.; Matsubara N.; Alekseev B.; Necchi A.; G?czi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Bedke J.; Gakis G.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; Garcia del Muro X.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Tagawa S.T.; Vaishampayan U.; Aragon-Ching J.B.; Hamid O.; Liepa A.M.; Wijayawardana S.; Russo F.; Walgren R.A.; Zimmermann A.H.; Hozak R.R.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Wan Ng S.S.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Culine S.; Becht C.; Niegisch G.; St?ckle M.; Grimm M.-O.; Schwentner C.A.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; R?v?sz J.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid D.; Scagliotti G.V.; Bracarda S.; Massari F.; Osawa T.; Miyajima N.; Shinohara N.; Fukuta F.; Ohyama C.; Obara W.; Yamashita S.; Tomita Y.; Kawai K.; Fukasawa S.; Oyama M.; Yonese J.; Nagata M.; Uemura M.; Nishimura K.; Kawakita M.; Tsunemori H.; Hashine K.; Inokuchi J.; Yokomizo A.; Nagamori S.; Lee H.J.; Park S.H.; Rha S.Y.; Kim Y.J.; Lee Y.-G.; Vazquez Cort?s L.; Lorena Urzua Flores C.; Blaisse R.J.B.; Erdkamp F.L.G.; Aarts M.J.B.; Wojcik-Tomaszewska J.; Tomczak P.; Sikora-Kupis B.; Schenker M.; Herzal A.A.; Udrea A.A.; Karlov P.; Fomkin R.; Gajate Borau P.; Grande E.; Delgado Mignorance J.I.; Su Y.-L.; Li J.-R.; Lin C.-L.; Chia-Chi Lin; Yeh S.-P.; Erman M.; Urun Y.; Golovko Y.; Bondarenko I.; Sinielnikov I.; Crabb S.J.; Syndikus I.; Huddart R.; Sundar S.; Chowdhury S.; Sarwar N.; Flaig T.W.; Pan C.X.; Schwarz J.K.; Cultrera J.L.; Acs P.I.; Hainsworth J.D.; Herms B.T.; Lawler W.E.; Lowe T.E. |
| 臺大學術典藏 |
2022-08-19T00:21:13Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Shih J.-Y.; CHIUN HSU; Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-08-19T00:21:10Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Yang P.-C.; Chang G.-C.; CHIUN HSU; Gow C.-H.; Yang C.-H.; Shih J.-Y.; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P. |
| 臺大學術典藏 |
2022-06-27T07:06:37Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.; Yang C.-H.; CHONG-JEN YU; Shih J.-Y.; Hsu C.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:06:35Z |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
|
Shih J.-Y.; Gow C.-H.; CHONG-JEN YU; Yang C.-H.; Chang Y.-L.; Tsai M.-F.; Hsu Y.-C.; Chen K.-Y.; Su W.-P.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:06:33Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Yang C.-H.; Shih J.-Y.; Chen K.-C.; CHONG-JEN YU; Yang T.-Y.; Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:01:48Z |
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer
|
Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; Yuan A.; Shiau C.-W.; CHONG-JEN YU; Chen K.-F. |
| 臺大學術典藏 |
2022-02-18T08:26:03Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; CHIEH-CHANG CHEN; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2022-02-14T06:28:43Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; YU-JEN FANG; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:23Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; CHUN-JEN LIU; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:02Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 國立成功大學 |
2022 |
Immunotherapy for Cancer: Strategies of Immunomodulation Therapy in Combination with Conventional Approaches
|
Gupta, T.;Murtaza, Murtaza M.;Ghosh, M.;Su, W.P.;Pandey, N.K.;Goutam, U. |
| 國立成功大學 |
2022 |
Atomically dispersed golds on degradable zero-valent copper nanocubes augment oxygen driven Fenton-like reaction for effective orthotopic tumor therapy
|
Wang, L.-C.;Chang, L.-C.;Chen, W.-Q.;Chien, Y.-H.;Chang, P.-Y.;Pao, C.-W.;Liu, Y.-F.;Sheu, H.-S.;Su, W.-P.;Yeh, C.-H.;Yeh, C.-S. |
| 臺大學術典藏 |
2021-09-04T06:10:54Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; JIA-HORNG KAO; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; JIA-HORNG KAO; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2021-09-04T05:16:25Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-01T02:02:14Z |
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients
|
Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; ANN-LII CHENG; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; Chen P.-J. |
| 臺大學術典藏 |
2021-08-31T06:42:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-03T03:35:21Z |
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients
|
Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; Cheng A.-L.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:33:20Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:29Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; CHEN-HUA LIU; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2021-05-24T07:20:14Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
CHEN-HUA LIU; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-04-29T05:09:19Z |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
|
Shih J.-Y.; Gow C.-H.; Yu C.-J.; Yang C.-H.; Chang Y.-L.; Tsai M.-F.; Hsu Y.-C.; KUAN-YU CHEN; Su W.-P.; Yang P.-C. |
| 臺大學術典藏 |
2021-03-09T01:43:09Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; TUNG-HUNG SU; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-02-02T02:48:04Z |
Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients
|
Kao J.-T.; Lai H.-C.; Tsai S.-M.; Lin P.-C.; Chuang P.-H.; Yu C.-J.; Cheng K.-S.; Su W.-P.; PING-NING HSU; Peng C.-Y.; Wu Y.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:32Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; KUN-HUEI YEH; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
